Tasly Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tasly Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Tasly Pharmaceuticals: 8 sponsored US clinical trials, 1 recruiting.
Tasly Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Angina Pectoris, with 2 trials.
Upper-quartile sponsor footprint
Tasly Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
NCT03789552
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
NCT04993729
Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
NCT03552263
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
NCT01659580
Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese
NCT01679028
A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin
NCT01475279
A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes
NCT01473888
Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
NCT00797953
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Tasly Pharmaceuticals pipeline
1 recruiting of 8 indexed (13% open); 7 completed (88%).
Phase mix: 3 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Angina Pectoris (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tasly Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Tasly Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Tasly Pharmaceuticals page
8 registered trials is a research-attention snapshot, not an endorsement of Tasly Pharmaceuticals or any single study.
- 1 of Tasly Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Angina Pectoris is the condition Tasly Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Angina Pectoris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tasly Pharmaceuticals pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.